標(biāo)題: Titlebook: Biologic Therapy for Psoriasis; Cutting Edge Treatme Nicholas Brownstone,Tina Bhutani,Wilson Liao Book 2022 The Editor(s) (if applicable) a [打印本頁] 作者: Disaster 時間: 2025-3-21 18:44
書目名稱Biologic Therapy for Psoriasis影響因子(影響力)
書目名稱Biologic Therapy for Psoriasis影響因子(影響力)學(xué)科排名
書目名稱Biologic Therapy for Psoriasis網(wǎng)絡(luò)公開度
書目名稱Biologic Therapy for Psoriasis網(wǎng)絡(luò)公開度學(xué)科排名
書目名稱Biologic Therapy for Psoriasis被引頻次
書目名稱Biologic Therapy for Psoriasis被引頻次學(xué)科排名
書目名稱Biologic Therapy for Psoriasis年度引用
書目名稱Biologic Therapy for Psoriasis年度引用學(xué)科排名
書目名稱Biologic Therapy for Psoriasis讀者反饋
書目名稱Biologic Therapy for Psoriasis讀者反饋學(xué)科排名
作者: 能夠支付 時間: 2025-3-21 22:44
Asthma bronchiale im Kindesalterherapy can pose potential risks for patients with concomitant chronic infections including human immunodeficiency virus (HIV), tuberculosis (TB), hepatitis B (HBV), and hepatitis C (HCV). To date, many of these drugs have not been thoroughly studied for patients with chronic infections. Prescreening作者: 賞心悅目 時間: 2025-3-22 03:39 作者: ungainly 時間: 2025-3-22 08:23
https://doi.org/10.1007/978-3-642-36999-5tor of this pathway, and overexpression of IL-17A results in epidermal hyperplasia and an inflammatory response, resulting in skin plaques and systemic inflammation. Targeted anti-IL-17 therapies have demonstrated efficacy and a favorable safety profile in key phase III clinical trials. Furthermore,作者: 積云 時間: 2025-3-22 09:14 作者: FOLD 時間: 2025-3-22 13:59 作者: Pageant 時間: 2025-3-22 20:28
Kinderallergologie in Klinik und Praxisntial for, or presence of, associated comorbidities and the chronicity of psoriasis warrant systemic treatment in a subset of children with moderate-to-severe disease. Recent data have shown that biologics offer a safe and effective option for children. Currently, etanercept, ustekinumab, ixekizumab作者: 確認(rèn) 時間: 2025-3-22 23:16 作者: Narcissist 時間: 2025-3-23 03:07
Hagen Ott,Lars Lange,Matthias V. Koppdates for full-body therapy with either phototherapy or systemic agents. There is extensive evidence of efficacy and safety of the newer systemic therapies, biologics, of which there are currently 11 FDA-approved. They are compared directly to each other in head-to-head trials and indirectly through作者: 殺子女者 時間: 2025-3-23 08:07 作者: Melodrama 時間: 2025-3-23 13:27 作者: dearth 時間: 2025-3-23 15:20
J. Busse,J. Jenke,R. K?ppen,E. Klaschikmay increase the risk of certain opportunistic infections, large registry studies suggest that these patients are not at an increased risk of COVID-19 infection, nor are they at an increased risk of more severe outcomes of COVID-19 infection. In fact, some data suggest psoriasis patients on biologic作者: Negotiate 時間: 2025-3-23 21:43
J. Busse,J. Jenke,R. K?ppen,E. Klaschikon patient quality of life, adherence to these drugs remains suboptimal. Barriers to adherence include side effects, poor socioeconomic status, high medication costs, and problems with insurance coverage. Increased biologic adherence is associated with the use of ustekinumab, combination treatment, 作者: 課程 時間: 2025-3-24 00:51 作者: 鉆孔 時間: 2025-3-24 04:50
Updates in Clinical Dermatologyhttp://image.papertrans.cn/b/image/187288.jpg作者: 舔食 時間: 2025-3-24 08:02
https://doi.org/10.1007/978-3-030-92938-1psoriasis; biologics; biologic therapy; combination therapy; pediatric psoriasis; geriatric psoriasis作者: 字形刻痕 時間: 2025-3-24 13:27 作者: 沒血色 時間: 2025-3-24 16:36 作者: Instantaneous 時間: 2025-3-24 20:57
Book 2022rtly caused by a dysregulated immune system resulting in?well-demarcated red areas of the skin with white scales, biologic therapy has the potential to vastly improve upon patient outcomes by minimizing the symptoms of?this disease while maximizing the safety profile of the therapy.??..?..This book 作者: obeisance 時間: 2025-3-25 01:14 作者: 不能強(qiáng)迫我 時間: 2025-3-25 06:06
https://doi.org/10.1007/978-3-642-36999-5 IL-17 antagonists have also shown sustained treatment responses and a quick onset of action. The high response rate seen in IL-17 inhibitors in the treatment of moderate-to-severe psoriasis underscores the importance of the IL-23/Th17 pathway in the pathogenesis of psoriasis.作者: 珊瑚 時間: 2025-3-25 11:02
2523-8884 h.Examines the 11 FDA approved biologic agents currently on .Biologic therapy is a treatment that strives to?modulate?a patient‘s immune system to fight a given disease. In psoriasis, a skin disorder that?is?partly caused by a dysregulated immune system resulting in?well-demarcated red areas of the 作者: PANIC 時間: 2025-3-25 15:09
Kinderallergologie in Klinik und Praxisused in psoriasis is presented. Finally, outcome measures in psoriasis clinical trials are also introduced with the goal of making it easier to interpret results from research and development of psoriasis biologic agents.作者: Scintillations 時間: 2025-3-25 16:04
Genetik, Epidemiologie und Pr?vention context of association between increased efficacy, infection, and malignancy. Delineation of the beneficial and deleterious effects of these medications fosters greater precision in appropriate regimen selection.作者: 使腐爛 時間: 2025-3-25 23:04
Kinderallergologie in Klinik und Praxiso-severe disease. Recent data have shown that biologics offer a safe and effective option for children. Currently, etanercept, ustekinumab, ixekizumab, and secukinumab are approved by the Food and Drug Administration for treatment in children. Approach to the use of biologics for pediatric psoriasis is detailed in this chapter.作者: 試驗 時間: 2025-3-26 02:57 作者: Arresting 時間: 2025-3-26 06:18
Introduction to Biologic Therapy for Psoriasis,used in psoriasis is presented. Finally, outcome measures in psoriasis clinical trials are also introduced with the goal of making it easier to interpret results from research and development of psoriasis biologic agents.作者: 人充滿活力 時間: 2025-3-26 09:15
TNF-Alpha Class of Biologic Agents in Psoriatic Disease, context of association between increased efficacy, infection, and malignancy. Delineation of the beneficial and deleterious effects of these medications fosters greater precision in appropriate regimen selection.作者: CRASS 時間: 2025-3-26 13:07 作者: 原始 時間: 2025-3-26 19:24
Special Site Psoriasis,r in patients’ quality of life, localization of psoriasis to specialized areas of the body can also cause stigmatization and physical and psychosocial burden. In this chapter, we will review treatment options for special sites of psoriasis, focusing on the efficacy and safety of biologic agents.作者: 領(lǐng)袖氣質(zhì) 時間: 2025-3-26 21:14 作者: 冰河期 時間: 2025-3-27 04:58 作者: burnish 時間: 2025-3-27 07:28
J. Busse,J. Jenke,R. K?ppen,E. Klaschiklogics..The emergence of teledermatology during the COVID-19 pandemic became a convenient and desirable option for some psoriasis patients on biologic therapy and may serve as a suitable modality of care for these patients beyond the pandemic.作者: Urologist 時間: 2025-3-27 13:15
J. Busse,J. Jenke,R. K?ppen,E. Klaschikcs in the treatment of psoriasis. Although adherence is less than ideal for most biologics, there are strategies to improve adherence and drug survival, including early follow-up consultations, anchoring, electronic reminders, and consideration of patient preferences to create a tailored treatment regimen.作者: lipids 時間: 2025-3-27 15:22 作者: Individual 時間: 2025-3-27 20:27 作者: 擦掉 時間: 2025-3-28 00:05 作者: meritorious 時間: 2025-3-28 02:51 作者: 細(xì)菌等 時間: 2025-3-28 07:17 作者: Spinous-Process 時間: 2025-3-28 10:31
IL-23 Class of Biologic Agents in Psoriatic Disease,mab, risankizumab), we have observed unprecedented clinical improvements in the skin and joints of patients affected by psoriasis. IL-23 inhibition has set a new standard for clinical efficacy, treatment durability, and overall safety for the treatment of psoriatic disease.作者: 指派 時間: 2025-3-28 14:57
Laboratory Monitoring: HIV, TB and Hepatitis, for TB, HBV, and HCV is necessary prior to treatment with a biologic agent. Prescreening for HIV is advised in patients with risk factors. The presence of chronic infection does not preclude treatment with a biologic therapy; however, these patients must be followed closely by an interdisciplinary team to ensure the best possible outcomes.作者: 造反,叛亂 時間: 2025-3-28 20:36 作者: 低三下四之人 時間: 2025-3-28 23:56 作者: 好色 時間: 2025-3-29 03:32
Laboratory Monitoring: HIV, TB and Hepatitis,herapy can pose potential risks for patients with concomitant chronic infections including human immunodeficiency virus (HIV), tuberculosis (TB), hepatitis B (HBV), and hepatitis C (HCV). To date, many of these drugs have not been thoroughly studied for patients with chronic infections. Prescreening作者: 極小量 時間: 2025-3-29 10:57 作者: Arrhythmia 時間: 2025-3-29 13:44 作者: Stress-Fracture 時間: 2025-3-29 15:36 作者: amorphous 時間: 2025-3-29 21:07
Combination Therapy with Biologic Agents, the advent of various biologic agents for the treatment of moderate-to-severe psoriasis, it is now possible for many patients to achieve adequate disease control with subsequent improvement in quality of life. However, in some circumstances, combining a biologic agent with one or more additional th作者: Bronchial-Tubes 時間: 2025-3-30 02:51 作者: 轉(zhuǎn)換 時間: 2025-3-30 07:13
